Yellow fever vaccine - GE Healthcare

Drug Profile

Yellow fever vaccine - GE Healthcare

Alternative Names: XRX-001; XRX-001 inactivated yellow fever vaccine - GE Healthcare; XRX-001 yellow fever 17D, inactivated vaccine, alum adsorbed - GE Healthcare

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xcellerex
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Yellow fever

Highest Development Phases

  • No development reported Yellow fever

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Yellow-fever(Prevention) in USA (Parenteral, Injection)
  • 07 Apr 2011 Yellow fever vaccine - Xcellerex is available for licensing as of 07 Apr 2011.
  • 07 Apr 2011 Immunogenicity and adverse events data from a phase I trial in Healthy volunteers released by Xcellerex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top